118 related articles for article (PubMed ID: 37949314)
1. Effect of increase in heart rate after anthracycline chemotherapy on subsequent left ventricular dysfunction.
Kintsu M; Odajima S; Takeuchi K; Ichikawa Y; Todo S; Ota E; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Minami H; Hirata KI; Tanaka H
J Cardiol; 2024 Aug; 84(2):119-125. PubMed ID: 37949314
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
3. Baseline Global Longitudinal Strain as a Predictor of Left Ventricular Dysfunction and Hospitalization for Heart Failure of Patients With Malignant Lymphoma After Anthracycline Therapy.
Hatazawa K; Tanaka H; Nonaka A; Takada H; Soga F; Hatani Y; Matsuzoe H; Shimoura H; Ooka J; Sano H; Mochizuki Y; Matsumoto K; Hirata KI
Circ J; 2018 Sep; 82(10):2566-2574. PubMed ID: 29984789
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
5. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
[TBL] [Abstract][Full Text] [Related]
6. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
8. Association between clinical risk factors and left ventricular function in patients with breast cancer following chemotherapy.
Yamashita K; Tanaka H; Hatazawa K; Tanaka Y; Sumimoto K; Shono A; Suzuki M; Yokota S; Suto M; Mukai J; Takada H; Matsumoto K; Minami H; Hirata KI
Int J Cardiovasc Imaging; 2021 Jan; 37(1):197-205. PubMed ID: 32860123
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
10. Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection.
Giang M N; Nguyen H H; Vo DT; Ho Huynh Quang T; Phan DTH; Chau NH
Open Heart; 2023 Nov; 10(2):. PubMed ID: 38011990
[TBL] [Abstract][Full Text] [Related]
11. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Gujral DM; Lloyd G; Bhattacharyya S
Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
[TBL] [Abstract][Full Text] [Related]
12. Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy.
Vera T; D'Agostino RB; Jordan JH; Whitlock MC; Meléndez GC; Lamar ZS; Porosnicu M; Bonkovsky HL; Poole LB; Hundley WG
Am J Cardiol; 2015 Dec; 116(11):1752-5. PubMed ID: 26433273
[TBL] [Abstract][Full Text] [Related]
13. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
14. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling.
Mizia-Stec K; Gościńska A; Mizia M; Haberka M; Chmiel A; Poborski W; Gąsior Z
Kardiol Pol; 2013; 71(7):681-90. PubMed ID: 23907900
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction.
Zhang KW; Finkelman BS; Gulati G; Narayan HK; Upshaw J; Narayan V; Plappert T; Englefield V; Smith AM; Zhang C; Hundley WG; Ky B
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1059-1068. PubMed ID: 29550306
[TBL] [Abstract][Full Text] [Related]
18. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.
Valdés Olmos RA; ten Bokkel Huinink WW; ten Hoeve RF; van Tinteren H; Bruning PF; van Vlies B; Hoefnagel CA
Ann Oncol; 1994 Sep; 5(7):617-22. PubMed ID: 7993837
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy.
Oatmen KE; Toro-Salazar OH; Hauser K; Zellars KN; Mason KC; Hor K; Gillan E; Zeiss CJ; Gatti DM; Spinale FG
Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1443-H1452. PubMed ID: 30141982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
